Ixabepilone-Induced Delirium

Tzu-Ching Yang^{1

2}, Yi-Wei Yeh², Fang-Jung Wan², Tzu-Chuan Huang³, Shiue-Wei Lai³, Nian-Sheng Tzeng^{2

4}

Affiliations

¹ Department of Psychiatry, Tri-Service General Hospital, Beitou Branch, National Defense Medical Center, Taipei, Taiwan.
² Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan.
³ Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan; and.
⁴ Student Counseling Center, National Defense Medical Center, Taipei, Taiwan e-mails: Tzu-Ching Yang, MD: chriswind27@gmail.com.

Case Reports

Tzu-Ching Yang et al. Am J Ther. 2024 Sep-Oct.

. 2024 Sep-Oct;31(5):e556-e557.

doi: 10.1097/MJT.0000000000001677.

Tzu-Ching Yang^{1

2}, Yi-Wei Yeh², Fang-Jung Wan², Tzu-Chuan Huang³, Shiue-Wei Lai³, Nian-Sheng Tzeng^{2

4}

¹ Department of Psychiatry, Tri-Service General Hospital, Beitou Branch, National Defense Medical Center, Taipei, Taiwan.
² Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan.
³ Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan; and.
⁴ Student Counseling Center, National Defense Medical Center, Taipei, Taiwan e-mails: Tzu-Ching Yang, MD: chriswind27@gmail.com.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

1. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291:1753–1762.
1. Hayhurst CJ, Marra A, Han JH, et al. Association of hypoactive and hyperactive delirium with cognitive function after critical illness. Crit Care Med. 2020;48:e480–e488.
1. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407–3414.
1. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
1. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415–3420.